AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by fibrillar neuronal inclusions containing aggregated α-synuclein (α-Syn). While the pathology of PD is multifaceted, the aggregation of α-Syn and mitochondrial dysfunction are well-established hallmarks in its pathogenesis. Recently, TFE3, a transcription factor, has emerged as a regulator of autophagy and metabolic processes. However, it remains unclear whether TFE3 can facilitate the degradation of α-Syn and regulate mitochondrial metabolism specifically in dopaminergic neurons. In this study, we demonstrate that TFE3 overexpression significantly mitigates the loss of dopaminergic neurons and reduces the decline in tyrosine hydroxylase-positive fiber density, thereby restoring motor function in an α-Syn overexpression model of PD. Mechanistically, TFE3 overexpression reversed α-Syn-mediated impairment of autophagy, leading to enhanced α-Syn degradation and reduced aggregation. Additionally, TFE3 overexpression inhibited α-Syn propagation. TFE3 overexpression also reversed the down-regulation of Parkin, promoting the clearance of accumulated mitochondria, and restored the expression of PGC1-α and TFAM, thereby enhancing mitochondrial biogenesis in the adeno-associated virus-α-Syn model. These findings further underscore the neuroprotective role of TFE3 in PD and provide insights into its underlying mechanisms, suggesting TFE3 as a potential therapeutic target for PD.
Abrishamdar M, Jalali MS, Farbood Y. Targeting mitochondria as a therapeutic approach for Parkinson’s disease. Cell Mol Neurobiol. 2023;43(4):1499-1518.
Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the pipeline targeting α-synuclein for Parkinson’s disease. Pharmacol Rev. 2022;74(1):207-237.
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045-2047.
Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41(12):1303-1307.
Hou X, Watzlawik JO, Fiesel FC, Springer W. Autophagy in Parkinson’s disease. J Mol Biol. 2020;432(8):2651-2672.
Haque ME, Akther M, Azam S, et al. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson’s disease. Br J Pharmacol. 2022;179(1):23-45.
Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009-25013.
Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci. 2011;31(41):14508-14520.
Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson’s disease - a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18(1):83.
Prasuhn J, Davis RL, Kumar KR. Targeting mitochondrial impairment in Parkinson’s disease: challenges and opportunities. Front Cell Dev Biol. 2020;8:615461.
Li W, Fu Y, Halliday GM, Sue CM. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease. Front Cell Dev Biol. 2021;9:612476.
Li J, Yang D, Li Z, et al. PINK1/Parkin-mediated mitophagy in neurodegenerative diseases. Ageing Res Rev. 2023;84:101817.
Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease. Mol Neurodegener. 2020;15(1):20.
Chen C, Vincent AE, Blain AP, Smith AL, Turnbull DM, Reeve AK. Investigation of mitochondrial biogenesis defects in single substantia nigra neurons using post-mortem human tissues. Neurobiol Dis. 2020;134:104631.
Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2(52):52ra73.
Moradi Vastegani S, Nasrolahi A, Ghaderi S, et al. Mitochondrial dysfunction and Parkinson’s disease: pathogenesis and therapeutic strategies. Neurochem Res. 2023;48(8):2285-2308.
Martina JA, Diab HI, Li L, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7(309):ra9.
Lin W, Li Z, Liang G, et al. TNEA therapy promotes the autophagic degradation of NLRP3 inflammasome in a transgenic mouse model of Alzheimer’s disease via TFEB/TFE3 activation. J Neuroinflammation. 2023;20(1):21.
Xu Y, Hu X, Li F, et al. GDF-11 protects the traumatically injured spinal cord by suppressing pyroptosis and necroptosis via TFE3-mediated autophagy augmentation. Oxid Med Cell Longev. 2021;2021:8186877.
Zhou K, Zheng Z, Li Y, et al. TFE3, a potential therapeutic target for spinal cord injury via augmenting autophagy flux and alleviating ER stress. Theranostics. 2020;10(20):9280-9302.
He X, Xie Y, Zheng Q, et al. TFE3-mediated autophagy is involved in dopaminergic neurodegeneration in Parkinson’s disease. Front Cell Dev Biol. 2021;9:761773.
Li X, Chen Y, Gong S, et al. Emerging roles of TFE3 in metabolic regulation. Cell Death Dis. 2023;9(1):93.
Wang B, Yin X, Gan W, et al. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma. Autophagy. 2021;17(9):2475-2493.
Monville C, Torres EM, Dunnett SB. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Methods. 2006;158(2):219-223.
Guo L, Xiong H, Kim JI, et al. Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson’s disease. Nat Neurosci. 2015;18(9):1299-1309.
Huntington TE, Srinivasan R. Adeno-associated virus expression of α-synuclein as a tool to model Parkinson’s disease: current understanding and knowledge gaps. Aging Dis. 2021;12(4):1120-1137.
Bellomo G, Paciotti S, Gatticchi L, Parnetti L. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction. Mov Disord. 2020;35(1):34-44.
Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A. 2013;110(19):E1817-E1826.
Spencer B, Potkar R, Trejo M, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci. 2009;29(43):13578-13588.
Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One. 2010;5(2):e9313.
Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739-29752.
Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis. 2016;6(1):39-51.
Guo YJ, Xiong H, Chen K, Zou JJ, Lei P. Brain regions susceptible to alpha-synuclein spreading. Mol Psychiatr. 2022;27(1):758-770.
Chen L, Xie Z, Turkson S, Zhuang X. A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J Neurosci. 2015;35(3):890-905.
Chung E, Choi Y, Park J, et al. Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological α-synuclein. Sci Adv. 2020;6(18):eaba1193.
Wilkaniec A, Lenkiewicz AM, Babiec L, et al. Exogenous alpha-synuclein evoked parkin downregulation promotes mitochondrial dysfunction in neuronal cells. implications for Parkinson’s disease pathology. Front Aging Neurosci. 2021;13:591475.
Park JH, Burgess JD, Faroqi AH, et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol Neurodegener. 2020;15(1):5.
Salma N, Song JS, Arany Z, Fisher DE. Transcription factor Tfe3 directly regulates Pgc-1 alpha in muscle. J Cell Physiol. 2015;230(10):2330-2336.
Cheng CF, Ku HC, Lin H. PGC-1α as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci. 2018;19(11):3447.
Liu J, Jiang J, Qiu J, et al. Urolithin A protects dopaminergic neurons in experimental models of Parkinson’s disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1α signaling pathway. Food Funct. 2022;13(1):375-385.
Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion. 2007;7(1–2):39-44.
Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther. 2017;23(1):5-22.
Cerri S, Blandini F. Role of autophagy in Parkinson’s disease. Curr Med Chem. 2019;26(20):3702-3718.
Lu J, Wu M, Yue Z. Autophagy and Parkinson’s disease. Adv Exp Med Biol. 2020;1207:21-51.
Liu H, Dai C, Fan Y, et al. From autophagy to mitophagy: the roles of P62 in neurodegenerative diseases. J Bioenerg Biomembr. 2017;49(5):413-422.
Lu H, Zhu C, Ruan Y, et al. TFE3 regulates the function of the autophagy-lysosome pathway to drive the invasion and metastasis of papillary thyroid carcinoma. Anal Cell Pathol. 2021;2021:3081491.
Fowler AJ, Moussa CEH. Activating autophagy as a therapeutic strategy for Parkinson’s disease. CNS Drugs. 2018;32(1):1-11.
Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001;293(5528):263-269.
Lonskaya I, Desforges NM, Hebron ML, Moussa CE. Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance. PLoS One. 2013;8(12):e83914.
Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113(5):1263-1274.
Li J, Lou J, Yu G, et al. Targeting TFE3 protects against lysosomal malfunction-induced pyroptosis in random skin flaps via ROS elimination. Front Cell Dev Biol. 2021;9:643996.
Chen C, Turnbull DM, Reeve AK. Mitochondrial dysfunction in Parkinson’s disease-cause or consequence? Biology. 2019;8(2):38.
Wang XL, Feng ST, Wang YT, et al. Mitophagy, a form of selective autophagy, plays an essential role in mitochondrial dynamics of Parkinson’s disease. Cell Mol Neurobiol. 2022;42(5):1321-1339.
Lin MW, Lin CC, Chen YH, Yang HB, Hung SY. Celastrol inhibits dopaminergic neuronal death of Parkinson’s disease through activating mitophagy. Antioxidants. 2019;9(1):37.
Wang Z, Cui J, Li D, Ran S, Huang J, Chen G. Morin exhibits a neuroprotective effect in MPTP-induced Parkinson’s disease model via TFEB/AMPK-mediated mitophagy. Phytomedicine. 2023;116:154866.
Harper JW, Ordureau A, Heo JM. Building and decoding ubiquitin chains for mitophagy. Nat Rev Mol Cell Biol. 2018;19(2):93-108.
Hsu YL, Chen HJ, Gao JX, Yang MY, Fu RH. Chiisanoside mediates the parkin/ZNF746/PGC-1α axis by downregulating miR-181a to improve mitochondrial biogenesis in 6-OHDA-caused neurotoxicity models in vitro and in vivo: suggestions for prevention of Parkinson’s disease. Antioxidants. 2023;12(9):1782.
Lin CY, Huang YN, Fu RH, Liao YH, Kuo TY, Tsai CW. Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1α by parkin as a mechanism of neuroprotection by carnosic acid. Phytomedicine. 2021;80:153369.
Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. J Neurosci Res. 2017;95(10):2025-2029.
Zheng Q, Liu H, Zhang H, et al. Ameliorating mitochondrial dysfunction of neurons by biomimetic targeting nanoparticles mediated mitochondrial biogenesis to boost the therapy of Parkinson’s disease. Adv Sci. 2023;10(22):e2300758.
Hsu HT, Yang YL, Chang WH, et al. Hyperbaric oxygen therapy improves Parkinson’s disease by promoting mitochondrial biogenesis via the SIRT-1/PGC-1α pathway. Biomolecules. 2022;12(5):661.
Kuiper RP, Schepens M, Thijssen J, Schoenmakers EFPM, van Kessel AG. Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains. Nucleic Acids Res. 2004;32(8):2315-2322.
Bordi M, Berg MJ, Mohan PS, et al. Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy. 2016;12(12):2467-2483.
Song JX, Liu J, Jiang Y, Wang ZY, Li M. Transcription factor EB: an emerging drug target for neurodegenerative disorders. Drug Discov Today. 2021;26(1):164-172.
Chen M, Dai Y, Liu S, Fan Y, Ding Z, Li D. TFEB biology and agonists at a glance. Cells. 2021;10(2):333.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
京公网安备11010802044758号